EarCentric EX2 vs Lexie B3

The EarCentric EX2 is a behind-the-ear prescription hearing aid priced at $218, positioning it as a budget-friendly option in the prescription category. In HearAdvisor's lab testing, it earned a C grade with a SoundScore of 2.7/5, ranking #35 of 39 prescription hearing aids tested. This 2021 release demonstrates mixed performance across key metrics. Its standout strength is feedback handling, scoring an excellent 4.7/5—essentially matching the category average and indicating reliable stability during movement. However, speech performance is a significant weakness: speech in quiet scores just 1.0/5 (2.40 points below the category average of 3.40), and speech in noise scores 1.0/5 (1.11 points below average). These low absolute scores suggest limited audibility enhancement in our standardized test conditions. Own-voice comfort scores 2.3/5, which is mixed in absolute terms and 0.40 points below the category average. Music streaming scored 0.0/5, indicating this device is not suited for audio entertainment purposes. The EarCentric EX2 may appeal to budget-conscious consumers who prioritize cost over performance, but alternatives exist at similar or lower price points with stronger test results. The RxEars Rxi, available in the same price range, scored 4.07/5 in our testing. Consumers seeking entry-level amplification should weigh the significant speech clarity limitations against the low purchase price.

The Lexie B3 is a mid-priced OTC hearing aid available at $999 that achieves an A grade with a SoundScore of 4.7/5 in our lab testing, ranking #1 among 65 OTC hearing aid devices tested. This behind-the-ear style device delivers category-leading performance across multiple metrics. Speech clarity is a standout strength. In our lab testing, the Lexie B3 scores an excellent 4.5/5 for speech in quiet, measuring 1.73 points above the OTC category average. Speech in noise performance scores 2.5/5—above the category average by 1.02 points, though only mixed in absolute terms at 2.5/5. This pattern reflects the broader challenge OTC devices face in noisy environments while still positioning the B3 as a top performer relative to its category. Music streaming quality is solid at 3.3/5, outperforming the category average by 1.38 points. Own-voice comfort scores a solid 3.0/5, sitting 0.49 points above average. Feedback handling is excellent at 4.6/5, essentially matching the already-strong category average. The Lexie B3 is best suited for consumers seeking top-tier OTC sound performance without prescription hearing aid costs. Those who prioritize speech clarity in quieter settings will find particular value here. Budget-conscious shoppers may want to consider alternatives like the RxEars Rxi, which offers strong performance at a lower price point.